IN8bio, Inc (INAB) Appoints Jeremy Graff to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
May 1, 2023 8:00 AM EDTDr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lillys oncology portfolioHe is a highly respected industry leader in oncology with a track record of success in advancing multiple novel anti-cancer compounds into and through the clinic and has been instrumental in garnering the approval of several oncology products
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq:... More
